top of page

Highlights

  • Instant results using a color-coded system

  • Eliminates ineligible pathways in seconds

  • Backed by interpretable automated reports

  • ​Match patients with suitable devices and related trials

  • ​Focus on viable treatment paths that matter to the patient

One click Pre-Screening: AI driven assessments of patient eligibility

REC Rapid Eligibility Check

How it works

Dr. Matti Adam

Interventional cardiologist | University Hospital, Cologne

"The ability to quickly and accurately assess patient eligibility for mitral valve procedures has significantly improved the workflow in our research project.
 
I'm convinced that this is a game changer that will allow us to focus on the viable treatment pathways and improve the care of our patients.”​
​

Julian Praceus

CEO and Co-Founder LARALAB GmbH

"REC is set to save substantial time for heart teams by swiftly indicating viable pathways and eliminating ineligible options for patients.
 
The patient screening for new Mitral and Tricuspid interventions is extensive - it works in a trial setting but not yet to serve the large number of patients in need. We designed REC to enable this transition.”

The first data for Mitral Valve - TMVR was presented at New York Valves 2024

Streamlining Transcatheter Mitral Valve Replacement Screening: A Comparative Analysis of Fully Automated AI-Based CT Analysis versus Manual Core-Lab Approach

Presented by Dr. Jonathan Curio

PD Dr. Matti Adam, PD Dr. Mani Arsalan, Dr. Martin Beyer, Prof. Dr. Lenard Conradi, Dr. Jonathan Curio, Prof. Dr. David Leistner, PD Dr. Andreas Schäfer and Prof. Dr. Thomas Walther
Read the slides here

Presentation

New York, NY Valves Conference, 4th June 2024 | REC Pre-Screening resulted in "reliable anatomical measurements" and "good accuracy compared to Abbott core lab decision making" for Tendyne, presented by Jonathan Curio (University Hospital Cologne) and validated with the University Hospitals of Cologne, Hamburg and Frankfurt | Read the slides

Press Release

MUNICH, GERMANY, May 10, 2024 /EINPresswire.com/ LARALAB Launches Groundbreaking New Product 'REC - Rapid Eligibility Check'. REC offers rapid, AI-driven assessments of patient eligibility for various heart procedures, significantly improving the screening and decision-making process for structural heart teams worldwide. | Read press release

Latest News 

Get started with REC

REC is currently available for selected partners. Sign up for REC updates or apply for early access.

Disclaimer: The LARALAB Platform is CE-marked under MDR regulations. The REC Suite is released for research use only. 

bottom of page